Melanocortin Receptor Obesity Program

Palatin Technologies has an exclusive global licensing and research collaboration agreement with AstraZeneca AB, a major international pharmaceutical and healthcare business, to discover, develop and commercialize compounds that target melanocortin receptors for the treatment of obesity, diabetes and related metabolic syndrome.

The collaboration, based on Palatin’s melanocortin receptor program for the treatment of obesity, includes access to compound libraries, core technologies and expertise in melanocortin receptor drug discovery and development.

Palatin Technologies and AstraZeneca have made significant progress under the collaboration agreement, using core technologies in lead generation and expertise in melanocortin biology developed by Palatin Technologies.  A near term objective of the collaboration with AstraZeneca is to advance a lead drug candidate to clinical evaluation.

For more information on Palatin’s Melanocortin Receptor Obesity Program, download the fact sheet.